The New Brunswick, N.J.-based company said its application is for treating adults with manic or mixed episodes linked to bipolar I disorder. J&J said approval would make this the fifth adult use cleared for Caplyta.
The antipsychotic is already approved for depressive episodes associated with bipolar I or II disorder, schizophrenia and major depressive disorder. Last week, J&J said Caplyta met its key goals in a second late-stage study in bipolar mania.
Caplyta was a key asset in J&J’s $14.6 billion acquisition of Intra-Cellular Therapies last year.





Comments (0)
No comments yet. Be the first!